Overview - Schedule of Restatement of Previously Issued Consolidated Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Jul. 15, 2019
Cash and cash equivalents							$ 15,106	$ 2,321
Accounts receivable, net of allowance for doubtful accounts							7,239	10,338
Other current assets							3,751	3,851
Total current assets							26,096	16,510
Property and equipment, net							7,249	6,814
Other intangible assets, net							13,619	15,849
Goodwill							8,433	8,433	$ 8,300
Operating lease right of use assets							5,172
Other long-term assets							42	42
Total assets							60,611	51,540
Accounts payable							3,348	4,709
Accrued salary and bonus							2,247	2,341
Other accrued expenses							9,737	9,476
Current liabilities from discontinued operations							766	766
Total current liabilities							16,098	17,292
Contingent consideration							2,207	2,391
Operating lease liabilities, net of current portion							3,940	2,591
Line of credit							3,400	3,000
Other long-term liabilities							4,557	4,573
Total liabilities							30,202	29,847
Commitments and contingencies (Note 8)
Preferred stock value
Common stock value							402	393
Additional paid-in capital							182,980	182,514
Accumulated deficit							(197,739)	(185,665)
Treasury stock, at cost (11,781 shares)							(1,770)	(1,721)
Total stockholders' equity	$ 6,838	$ 6,838	$ 13,346	$ 32,938	$ (16,127)	$ 32,938	(16,127)	(4,479)
Total liabilities and stockholders' equity							14,075	25,368
Total liabilities, preferred stock and stockholders' equity							60,611	51,540
Revenue, net	5,446		6,270		14,504	12,280
Cost of revenue	3,850		3,031		9,963	5,654
Gross profit	1,596		3,239		4,541	6,626
Sales and marketing	1,596		2,959		4,077	5,369
Research and development	550		647		1,360	1,175
General and administrative	4,107		2,788		8,999	5,122
Acquisition related expense			1,295			1,696
Acquisition related amortization expense	1,115		897		2,230	1,794
Total operating expenses	7,368		8,586		16,666	15,156
Operating loss	(5,772)		(5,347)		(12,125)	(8,530)
Interest accretion	(167)		(91)		(276)	(220)
Other income (expense), net	438		74		485	123
Loss from continuing operations before tax	(5,501)		(5,364)		(11,916)	(8,627)
Provision for income taxes	13		5		28	10
Loss from continuing operations, net of tax	(5,514)		(5,369)		(11,944)	(8,637)
Less adjustment for preferred stock deemed dividend					3,033
Loss from continuing operations attributable to common stockholders	(5,580)		(5,304)		(12,074)	(8,630)
Loss from discontinued operations, net of tax	(66)		65		(130)	7
Net loss attributable to common stockholders	$ (5,580)		$ (5,304)		$ (15,107)	$ (8,630)
From continuing operations	$ (1.37)		$ (1.41)		$ (3.73)	$ (2.36)
From discontinued operations	(0.01)		0.02		(0.03)
Net loss per basic and diluted share of common stock	$ (1.38)		$ (1.39)		$ (3.76)	$ (2.36)
Basic	4,033,000		3,813,000		4,018,000	3,665,000
Diluted	4,033,000		3,813,000		4,018,000	3,665,000
Balance	$ 6,838	(4,479)	$ 35,771	32,938	$ (4,479)	$ 32,938
Common stock issued		1	73	1
Restricted stock issued
Common stock issued through market sales		484
Common stock issued through offerings				5,962
Treasury stock purchased	(49)			(32)
Extinguishment of Series A Shares		(828)
Beneficial Conversion Feature in connection with Series B Issuance		2,205
Amortization of Beneficial Conversion Feature		(2,205)
Stock-based compensation expense	400	418	205	266
Adoption of ASC 842				55
Net loss	(5,580)	(6,494)	(5,304)	(3,419)	(15,107)	(8,630)
Balance	(16,127)	6,838	13,346	35,771	(16,127)	13,346
Net loss					(12,074)	(8,630)
Depreciation and amortization					2,708	1,917
Interest accretion					276	220
Mark to market on warrants					(49)	(45)
Stock-based compensation	818		500		818	990
Bad debt expense					250	499
Other gains and expenses, net					0	18
Decrease (increase) in accounts receivable					2,849	(3,982)
(Increase) decrease in other current assets					(788)	(252)
(Decrease) increase in accounts payable					(1,361)	530
(Decrease) increase in accrued salaries and bonus					(94)	(261)
(Decrease) increase in accrued liabilities					759	1,097
Increase in long-term liabilities					33	114
Net cash used in operating activities					(6,673)	(7,785)
Purchase of property and equipment					(913)	(48)
Sale of property and equipment					0	13
Net cash provided by investing activity					(913)	(35)
Issuance of common stock, net of expenses					434	5,962
Borrowings on Line of Credit, net					400
Issuance of Series B preferred stock, net of expenses					19,537
Net cash provided by financing activities					20,371	5,962
Net increase (decrease) in cash and cash equivalents					12,785	(1,858)
Cash and cash equivalents - beginning		2,321	5,377	6,068	2,321	6,068
Cash and cash equivalents - ending	15,106		4,210	5,377	15,106	4,210
Common Stock [Member]
Total stockholders' equity	402	402	383	382	402	383	402	393
Balance	$ 402	$ 393	$ 382	$ 287	$ 393	$ 287
Balance, shares	4,055,000	3,932,000	3,819,000	2,877,000	3,932,000	2,877,000
Common stock issued		$ 1	$ 1	$ 1
Common stock issued, shares		37,000	10,000	9,000
Restricted stock issued
Restricted stock issued, shares		6,000
Common stock issued through market sales		$ 8
Common stock issued through market sales, shares		80,000
Common stock issued through offerings				$ 94
Common stock issued through offerings, shares				933
Treasury stock purchased
Treasury stock purchased, shares
Extinguishment of Series A Shares
Beneficial Conversion Feature in connection with Series B Issuance
Amortization of Beneficial Conversion Feature
Stock-based compensation expense
Adoption of ASC 842
Net loss
Balance	$ 402	$ 402	$ 383	$ 382	$ 402	$ 383
Balance, shares	4,055,000	4,055,000	3,829,000	3,819,000	4,055,000	3,829,000
Treasury Stock [Member]
Total stockholders' equity	$ (1,721)	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,770)	$ (1,712)	(1,770)	(1,721)
Balance	$ (1,721)	$ (1,721)	$ (1,712)	$ (1,680)	$ (1,721)	$ (1,680)
Balance, shares	12,000	12,000	10,000	7,000	12,000	7,000
Common stock issued
Common stock issued, shares
Restricted stock issued
Restricted stock issued, shares
Common stock issued through market sales
Common stock issued through market sales, shares
Common stock issued through offerings
Common stock issued through offerings, shares
Treasury stock purchased	$ (49)			$ (32)
Treasury stock purchased, shares	7,000			3,000
Extinguishment of Series A Shares
Beneficial Conversion Feature in connection with Series B Issuance
Amortization of Beneficial Conversion Feature
Stock-based compensation expense
Adoption of ASC 842
Net loss
Balance	$ (1,770)	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,770)	$ (1,712)
Balance, shares	19,000	12,000	10,000	10,000	19,000	10,000
Additional Paid-in Capital [Member]
Total stockholders' equity	$ 182,580	$ 182,580	$ 182,231	$ 181,954	$ 182,980	$ 182,231	182,980	182,514
Balance	182,580	182,514	181,954	175,820	182,514	175,820
Common stock issued			72
Restricted stock issued
Common stock issued through market sales		476
Common stock issued through offerings				5,868
Treasury stock purchased
Extinguishment of Series A Shares		(828)
Beneficial Conversion Feature in connection with Series B Issuance		2,205
Amortization of Beneficial Conversion Feature		(2,205)
Stock-based compensation expense	400	418	205	266
Adoption of ASC 842
Net loss
Balance	182,980	182,580	182,231	181,954	182,980	182,231
Accumulated Deficit [Member]
Total stockholders' equity	(192,159)	(192,159)	(167,556)	(162,252)	(197,739)	(167,556)	(197,739)	(185,665)
Balance	(192,159)	(185,665)	(162,252)	(158,981)	(185,665)	(158,981)
Common stock issued
Restricted stock issued
Common stock issued through market sales
Common stock issued through offerings
Treasury stock purchased
Extinguishment of Series A Shares
Beneficial Conversion Feature in connection with Series B Issuance
Amortization of Beneficial Conversion Feature
Stock-based compensation expense
Adoption of ASC 842				55
Net loss	(5,580)	(6,494)	(5,304)	(3,326)
Balance	(197,739)	(192,159)	(167,556)	(162,252)	$ (197,739)	(167,556)
Series B [Member]
Preferred stock value							46,536
Common stock issued, shares					27,000
As Previously Reported [Member]
Cash and cash equivalents							15,106
Accounts receivable, net of allowance for doubtful accounts							7,239
Other current assets							3,751
Total current assets							26,096
Property and equipment, net							7,249
Other intangible assets, net							31,439
Goodwill							8,433
Operating lease right of use assets							5,172
Other long-term assets							42
Total assets							78,431
Accounts payable							3,348
Accrued salary and bonus							2,247
Other accrued expenses							9,737
Current liabilities from discontinued operations							766
Total current liabilities							19,498
Contingent consideration							2,207
Operating lease liabilities, net of current portion							3,940
Line of credit							3,400
Other long-term liabilities							4,557
Total liabilities							30,202
Commitments and contingencies (Note 8)
Common stock value							402
Additional paid-in capital							182,980
Accumulated deficit							(179,919)
Treasury stock, at cost (11,781 shares)							(1,770)
Total stockholders' equity	6,838	6,838			$ 1,693		1,693
Total liabilities and stockholders' equity							31,895
Total liabilities, preferred stock and stockholders' equity							78,431
Revenue, net	5,446		6,270		14,645	12,280
Cost of revenue	3,850		3,031		9,963	5,654
Gross profit	1,596		3,239		4,682	6,626
Sales and marketing	1,596		2,959		4,077	5,369
Research and development	550		647		1,360	1,175
General and administrative	4,107		2,788		8,993	5,299
Acquisition related expense			1,295			1,696
Acquisition related amortization expense	1,031		813		2,062	1,626
Total operating expenses	7,284		8,502		16,492	15,165
Operating loss	(5,688)		(5,263)		(11,810)	(8,539)
Interest accretion	(167)		(91)		(276)	(220)
Other income (expense), net	438		74		485	123
Loss from continuing operations before tax	(5,417)		(5,280)		(11,601)	(8,636)
Provision for income taxes	13		5		28	10
Loss from continuing operations, net of tax	(5,430)		(5,285)		(11,629)	(8,646)
Less adjustment for preferred stock deemed dividend					(3,033)
Loss from continuing operations attributable to common stockholders	(5,430)		(5,285)		(14,662)	(8,646)
Loss from discontinued operations, net of tax	(66)		65		(130)	7
Net loss attributable to common stockholders	$ (5,496)		$ (5,220)		$ (14,792)	$ (8,639)
From continuing operations	$ (1.35)		$ (1.39)		$ (3.65)	$ (2.36)
From discontinued operations	(0.01)		0.02		(0.03)
Net loss per basic and diluted share of common stock	$ (1.36)		$ (1.37)		$ (3.68)	$ (2.36)
Basic	4,033,000		3,813,000		4,018,000	3,665,000
Diluted	4,033,000		3,813,000		4,018,000	3,665,000
Balance	$ 6,838
Balance	1,693	6,838			$ 1,693
Net loss					(11,759)	$ (8,639)
Depreciation and amortization					2,540	1,749
Interest accretion					276	220
Mark to market on warrants					(49)	(45)
Stock-based compensation					818	990
Bad debt expense					250	499
Other gains and expenses, net						18
Decrease (increase) in accounts receivable					2,708	(3,982)
(Increase) decrease in other current assets					(788)	(252)
(Decrease) increase in accounts payable					(1,464)	530
(Decrease) increase in accrued salaries and bonus					(94)	(141)
(Decrease) increase in accrued liabilities					856	1,154
Increase in long-term liabilities					33	114
Net cash used in operating activities					(6,673)	(7,785)
Purchase of property and equipment					(913)	(48)
Sale of property and equipment						13
Net cash provided by investing activity					(913)	(35)
Issuance of common stock, net of expenses					434	5,962
Borrowings on Line of Credit, net					400
Issuance of Series B preferred stock, net of expenses					19,537
Net cash provided by financing activities					20,371	5,962
Net increase (decrease) in cash and cash equivalents					12,785	(1,858)
Cash and cash equivalents - beginning		2,321	$ 5,377	6,068	2,321	6,068
Cash and cash equivalents - ending	15,106		4,210	5,377	15,106	4,210
As Previously Reported [Member] | Common Stock [Member]
Total stockholders' equity	402	402	383	382	393	383		393
Balance	$ 402	$ 393	$ 382	$ 287	$ 393	$ 287
Balance, shares	4,055,000	3,932,000	3,819,000	2,877,000	3,932,000	2,877,000
Common stock issued		$ 1	$ 1	$ 1
Common stock issued, shares		37,000	10,000	9,000
Restricted stock issued
Restricted stock issued, shares		6,000
Common stock issued through market sales		$ 8
Common stock issued through market sales, shares		80,000
Common stock issued through offerings				$ 94
Common stock issued through offerings, shares				933,000
Balance		$ 402	$ 383	$ 382		$ 383
Balance, shares		4,055,000	3,829,000	3,819,000		3,829,000
As Previously Reported [Member] | Treasury Stock [Member]
Total stockholders' equity	$ (1,770)	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,770)	$ (1,712)	(1,770)	(1,721)
Balance	$ (1,721)	$ (1,721)	$ (1,712)	$ (1,680)	$ (1,721)	$ (1,680)
Balance, shares	12,000	12,000	10,000	7,000	12,000	7,000
Treasury stock purchased	$ (49)			$ (32)
Treasury stock purchased, shares	7,000			3,000
Balance	$ (1,770)	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,770)	$ (1,712)
Balance, shares	19,000	12,000	10,000	10,000	19,000	10,000
As Previously Reported [Member] | Additional Paid-in Capital [Member]
Total stockholders' equity	$ 182,980	$ 182,580	$ 182,231	$ 181,954	$ 182,980	$ 182,231	182,980	182,514
Balance	182,580	182,514	181,954	175,820	182,514	175,820
Common stock issued			72
Common stock issued through market sales		476
Common stock issued through offerings				5,868
Extinguishment of Series A Shares		(828)
Beneficial Conversion Feature in connection with Series B Issuance		2,205
Amortization of Beneficial Conversion Feature		(2,205)
Stock-based compensation expense	400	418	205	266
Balance	182,980	182,580	182,231	181,954	182,980	182,231
As Previously Reported [Member] | Accumulated Deficit [Member]
Total stockholders' equity	(179,919)	(174,423)	(150,073)	(141,489)	(179,919)	(150,073)	(179,919)	(168,160)
Balance	(174,423)	(168,160)	(144,853)	(141,489)	(168,160)	(141,489)
Adoption of ASC 842				55
Net loss	(5,496)	(6,263)	(5,220)	(3,419)
Balance	(179,919)	(174,423)	(150,073)	(144,853)	(179,919)	(150,073)
As Previously Reported [Member] | Series B [Member]
Preferred stock value							46,536
Restatement Amount [Member]
Cash and cash equivalents
Accounts receivable, net of allowance for doubtful accounts
Other current assets
Total current assets
Property and equipment, net
Other intangible assets, net							(17,820)
Goodwill
Operating lease right of use assets
Other long-term assets
Total assets							(17,820)
Accounts payable
Accrued salary and bonus
Other accrued expenses
Current liabilities from discontinued operations
Total current liabilities
Contingent consideration
Operating lease liabilities, net of current portion
Line of credit
Other long-term liabilities
Total liabilities
Commitments and contingencies (Note 8)
Common stock value
Additional paid-in capital
Accumulated deficit							(17,820)
Treasury stock, at cost (11,781 shares)
Total stockholders' equity	(17,736)	(17,736)			(17,820)		(17,820)
Total liabilities and stockholders' equity							(17,820)
Total liabilities, preferred stock and stockholders' equity							(17,820)
Revenue, net					(141)
Cost of revenue
Gross profit					(141)
Sales and marketing
Research and development
General and administrative					6	(177)
Acquisition related expense
Acquisition related amortization expense	84		84		168	168
Total operating expenses	84		84		174	(9)
Operating loss	(84)		(84)		(315)	9
Interest accretion
Other income (expense), net
Loss from continuing operations before tax	(84)		(84)		(315)	9
Provision for income taxes
Loss from continuing operations, net of tax	(84)		(84)		(315)	9
Less adjustment for preferred stock deemed dividend
Loss from continuing operations attributable to common stockholders	(84)		(84)		(315)	9
Loss from discontinued operations, net of tax
Net loss attributable to common stockholders	$ (84)		$ (84)		$ (315)	$ 9
From continuing operations	$ (0.02)		$ (0.02)		$ (0.08)	$ 0.00
From discontinued operations
Net loss per basic and diluted share of common stock	$ (0.02)		$ (0.02)		$ (0.08)
Basic	4,033,000		3,813,000		4,018,000	3,665,000
Diluted	4,033,000		3,813,000		4,018,000	3,665,000
Balance	$ (17,736)
Balance	(17,820)	(17,736)			$ (17,820)
Net loss					(315)	$ 9
Depreciation and amortization					168	168
Interest accretion
Mark to market on warrants
Stock-based compensation
Bad debt expense
Other gains and expenses, net
Decrease (increase) in accounts receivable					141
(Increase) decrease in other current assets
(Decrease) increase in accounts payable					103
(Decrease) increase in accrued salaries and bonus						(120)
(Decrease) increase in accrued liabilities					(97)	(57)
Increase in long-term liabilities
Net cash used in operating activities
Purchase of property and equipment
Sale of property and equipment
Net cash provided by investing activity
Issuance of common stock, net of expenses
Borrowings on Line of Credit, net
Issuance of Series B preferred stock, net of expenses
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents - beginning
Cash and cash equivalents - ending
Restatement Amount [Member] | Common Stock [Member]
Total stockholders' equity
Balance
Common stock issued
Restricted stock issued
Restricted stock issued, shares
Common stock issued through market sales
Common stock issued through offerings
Balance
Restatement Amount [Member] | Treasury Stock [Member]
Total stockholders' equity
Balance
Balance, shares
Treasury stock purchased
Balance
Balance, shares
Restatement Amount [Member] | Additional Paid-in Capital [Member]
Total stockholders' equity
Balance
Common stock issued through market sales
Common stock issued through offerings
Extinguishment of Series A Shares
Beneficial Conversion Feature in connection with Series B Issuance
Amortization of Beneficial Conversion Feature
Stock-based compensation expense
Balance
Restatement Amount [Member] | Accumulated Deficit [Member]
Total stockholders' equity	(17,820)	(17,736)	(17,483)	(17,492)	(17,820)	(17,483)	(17,820)	$ (17,505)
Balance	(17,736)	(17,505)	(17,399)	(17,492)	(17,505)	(17,492)
Adoption of ASC 842
Net loss	(84)	(231)	(84)	93
Balance	$ (17,820)	$ (17,736)	$ (17,483)	$ (17,399)	$ (17,820)	$ (17,483)
Restatement Amount [Member] | Series B [Member]
Preferred stock value